Cellectar Biosciences announces strategic supply agreement with Lonetix for Actinium-225 and Astatine-211 to advance targeted alpha therapies

CAR-T Digest - August 2020

Weekly Digest - December 2025

16 December 2025: Cellectar Biosciences announces strategic supply agreement with Ionetix for Actinium-225 and Astatine-211 to advance targeted alpha therapies

Cellectar Biosciences announced a multi-year strategic supply agreement with Ionetix Corporation to secure clinical and commercial-scale supplies of the alpha-emitting radioisotopes Actinium-225 and Astatine-211, strengthening its capabilities in targeted alpha therapy development
Under the agreement, Ionetix will provide cGMP-grade Ac-225 and At-211 to support Cellectar’s radiotherapeutic programs through clinical development and into potential commercial launches, addressing a key bottleneck in the advancement of alpha-based oncology therapies
The partnership is expected to play a critical role in advancing CLR-225, Cellectar’s phospholipid radioconjugate candidate, as the company expands its pipeline beyond beta and Auger emitters toward alpha-emitting targeted therapies for difficult-to-treat solid tumors, including pancreatic cancer
By leveraging its proprietary phospholipid ether platform, Cellectar is able to deliver a range of radioisotopes directly to tumor cells and match the optimal isotope to each tumor type, with Ac-225 and At-211 offering highly localized, high-energy radiation designed to maximize tumor kill while limiting damage to healthy tissue
To support this collaboration, Ionetix is expanding its manufacturing infrastructure with the installation of a second cyclotron in Michigan, enabling dedicated commercial-scale production of Ac-225 and At-211 and reinforcing long-term supply readiness for Cellectar’s next-generation targeted alpha therapies